Junhwan Kim is the CEO of STRADVISION, a South Korean AI perception company building the vision software that teaches cars to see. After selling his facial recognition startup Olaworks to Intel in 2012 - the first full acquisition of a Korean firm by Intel - he pivoted into automotive AI and helped build STRADVISION into a company with over 3 million cumulative production units deployed, $331M in total funding, and a pending KOSDAQ IPO. His flagship product, SVNet, runs on 50+ vehicle models across 13+ OEM partners and can identify pedestrians, lanes, traffic signs, and obstacles in real time on low-power edge chips.
Jin Ho Hur is a Co-Founder and General Partner at HRZ Han River Partners, a Menlo Park-based early-stage venture capital firm that bridges Silicon Valley and Korea's tech ecosystem. A PhD in Computer Science from KAIST and a serial entrepreneur who built and led internet companies in Korea from the mid-1990s, Hur helped shape the country's early internet economy and served as Chairperson of the Korea Internet Association. He later transitioned into institutional investing via Translink Investment before co-founding Han River Partners, which in October 2024 launched a $100 million fund focused on AI and consumer sectors within the 'Korea Graph.' He also writes the popular Substack newsletter 'Two Cents,' covering global tech and startup trends for over 9,000 subscribers.
Kunwoo Lee is the CEO and Co-founder of BreezeBio (formerly GenEdit), a Brisbane, California-based biotech company pioneering non-viral gene delivery through its proprietary NanoGalaxy platform. A Siebel Scholar and Forbes 30 Under 30 honoree who earned his PhD from UC Berkeley-UCSF Joint Program in Bioengineering, Lee co-founded GenEdit in 2016 alongside Professor Niren Murthy and fellow researcher Hyo Min Park, building out a polymer nanoparticle library of thousands of chemically distinct compounds capable of delivering diverse genetic payloads to specific tissues. The company has raised over $118 million including a $60M Series B in February 2026, struck a landmark $644M collaboration deal with Genentech, and rebranded to BreezeBio to signal its pivot from platform company to clinical-stage therapeutics developer advancing BRZ-101 for Type 1 Diabetes.